The Post-Traumatic Stress Disorder (PTSD) drugs in development market research report provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Post-Traumatic Stress Disorder (PTSD). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued products.
GlobalData tracks 108 drugs in development for Post-Traumatic Stress Disorder (PTSD) by 90 companies/universities/institutes. The top development phase for Post-Traumatic Stress Disorder (PTSD) is preclinical with 58 drugs in that stage. The Post-Traumatic Stress Disorder (PTSD) pipeline has 101 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Post-Traumatic Stress Disorder (PTSD) pipeline products market are: Boehringer Ingelheim International, Artelo Biosciences and Mydecine Innovations Group.
The key targets in the Post-Traumatic Stress Disorder (PTSD) pipeline products market include 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 1A, and Glutamate Ionotropic Receptor NMDA Type Subunit.
The key mechanisms of action in the Post-Traumatic Stress Disorder (PTSD) pipeline product include 5-Hydroxytryptamine Receptor 2A Agonist with 17 drugs in Phase II. The Post-Traumatic Stress Disorder (PTSD) pipeline products include ten routes of administration with the top ROA being Oral and six key molecule types in the Post-Traumatic Stress Disorder (PTSD) pipeline products market including Small Molecule, and Synthetic Peptide.
Post-Traumatic Stress Disorder (PTSD) overview
Post-traumatic stress disorder (PTSD) is a mental health condition that’s triggered by experiencing or witnessing a traumatic event. Symptoms include flashbacks, nightmares, and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety medications, and cognitive therapy.
For a complete picture of Post-Traumatic Stress Disorder (PTSD)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
